AR023166A1 - Vacuna del virus de papiloma humano con particulas del tipo virus desensambladas y reensambladas - Google Patents

Vacuna del virus de papiloma humano con particulas del tipo virus desensambladas y reensambladas

Info

Publication number
AR023166A1
AR023166A1 ARP000101345A ARP000101345A AR023166A1 AR 023166 A1 AR023166 A1 AR 023166A1 AR P000101345 A ARP000101345 A AR P000101345A AR P000101345 A ARP000101345 A AR P000101345A AR 023166 A1 AR023166 A1 AR 023166A1
Authority
AR
Argentina
Prior art keywords
virus
vaccine
disassembled
reassembled
type particles
Prior art date
Application number
ARP000101345A
Other languages
English (en)
Spanish (es)
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26824774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR023166(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of AR023166A1 publication Critical patent/AR023166A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ARP000101345A 1999-03-26 2000-03-24 Vacuna del virus de papiloma humano con particulas del tipo virus desensambladas y reensambladas AR023166A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12652899P 1999-03-26 1999-03-26
US09/524,624 US6245568B1 (en) 1999-03-26 2000-03-13 Human papilloma virus vaccine with disassembled and reassembled virus-like particles

Publications (1)

Publication Number Publication Date
AR023166A1 true AR023166A1 (es) 2002-09-04

Family

ID=26824774

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101345A AR023166A1 (es) 1999-03-26 2000-03-24 Vacuna del virus de papiloma humano con particulas del tipo virus desensambladas y reensambladas

Country Status (19)

Country Link
US (2) US6245568B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP1165126B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4594534B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20020013516A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR023166A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE339222T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU778937B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2368391C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (4) CY1105779T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (4) DE122007000033I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1165126T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2270822T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR07C0026I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1165126I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (3) LU91328I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (3) NL300268I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1165126E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1165126T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2000057906A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
US6962777B1 (en) * 1997-09-05 2005-11-08 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps), homogeneous vlp and capsomere compositions produced by said methods; use thereof as vehicle for improved purification, and delivery of active agents
WO2001042780A1 (en) * 1999-12-09 2001-06-14 Medimmune, Inc. IN VITRO METHOD FOR DISASSEMBLY/REASSEMBLY OF PAPILLOMAVIRUS VIRUS-LIKE PARTICLES (VLPs)
CN100350972C (zh) * 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20060073530A1 (en) * 2001-08-15 2006-04-06 Olaf Schneewind Methods and compositions involving sortase B
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003213060A1 (en) * 2002-02-14 2003-09-04 Novavax, Inc. Optimization of gene sequences of chimeric virus-like particles for expression in insect cells
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DE10237639A1 (de) * 2002-08-13 2004-02-26 Martin-Luther-Universität Halle-Wittenberg Verfahren zur Herstellung von virusanalogen Partikeln durch in vitro-Assemblierung von Kapsomeren oder von Kapsomeren, an die biologisch aktive Makromoleküle gebunden sind, bei gleichzeitiger Verpackung der Makromoleküle
GB0220194D0 (en) * 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
AU2003287980B2 (en) 2002-11-01 2009-06-25 Glaxosmithkline Biologicals S.A. Drying process
DE60336581D1 (de) 2002-12-20 2011-05-12 Glaxosmithkline Biolog Sa Verwendung von HPV16 und HPV18 VLPs als Vakzine gegen eine oder mehrere onkogene HPV des Typus 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
EP1785433A4 (en) * 2004-07-01 2008-10-01 Tokyo Inst Tech VIRAL PARTICLE-LIKE CONSTRUCTION AND PROCESS FOR FORMING THE SAME IN PHYSIOLOGICAL CONDITIONS
PE20060958A1 (es) * 2005-01-25 2006-10-27 Wyeth Res Ireland Ltd Protectores contra el esfuerzo cortante en la microfiltracion de la cosecha
WO2007011711A2 (en) * 2005-07-14 2007-01-25 Mayo Foundation For Medical Education And Research Paramyxoviridae virus preparations
US20090105130A1 (en) * 2005-08-12 2009-04-23 Astellas Pharma Inc. Depsipeptide-containing injection solution
CN101291689B (zh) * 2005-09-01 2012-12-05 若泽·路易斯·努诺·阿雅拉 用于大规模接种系统的活抗原的疫苗稳定化制剂
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
CN101460636A (zh) * 2006-05-11 2009-06-17 伯克顿迪金森公司 从细胞中提取蛋白质的方法
US9207240B2 (en) 2007-11-14 2015-12-08 Arbor Vita Corporation Method of efficient extraction of protein from cells
EP2258380B1 (en) * 2008-03-31 2013-03-13 Morinaga Milk Industry Co., Ltd. Nucleic acid for imparting heat resistance to lactoferrin
DK2473596T3 (en) 2009-09-03 2018-01-22 Becton Dickinson Co METHODS AND COMPOSITIONS FOR DIRECT CHEMICAL LYSIS
FI3831406T3 (fi) 2010-08-23 2024-08-06 Wyeth Llc Neisseria meningitidis rlp2086 -antigeenien stabiileja formulaatioita
ES2864635T3 (es) 2010-09-10 2021-10-14 Wyeth Llc Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
MY198910A (en) 2012-03-09 2023-10-02 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP2015514696A (ja) 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
KR101559622B1 (ko) * 2012-07-30 2015-10-13 중앙대학교 산학협력단 인유두종바이러스 바이러스 유사입자의 고효율 정제방법
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
AU2014316722B2 (en) 2013-09-08 2017-09-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR20170103009A (ko) 2015-02-19 2017-09-12 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
CN118021947A (zh) 2017-01-31 2024-05-14 辉瑞大药厂 脑膜炎奈瑟菌组合物及其使用方法
WO2018152505A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Efficient cell free production of papillomavirus gene transfer vectors
KR102651043B1 (ko) 2017-10-30 2024-03-22 다케다 야쿠힌 고교 가부시키가이샤 지질-외피보유 바이러스의 불활성화를 위한 환경 친화적 세제
MX2022003682A (es) 2019-09-27 2022-04-25 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
CN110987571A (zh) * 2019-12-31 2020-04-10 广州金域医学检验中心有限公司 一种单克隆多聚体m蛋白解聚方法
CN111812313B (zh) * 2020-06-22 2021-10-08 北京生物制品研究所有限责任公司 铝佐剂吸附型新型冠状病毒灭活疫苗中抗原的解离方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE470434T1 (de) * 1997-02-06 2010-06-15 Merck Sharp & Dohme Thimerosal-freie konservierungsmittel für impfstoffe
NZ500028A (en) 1997-04-08 2001-08-31 Merck & Co Inc Stabilized human papillomavirus formulations also containing a salt and a nonionic surfactant
EP1000157A1 (en) 1997-07-03 2000-05-17 University Technology Corporation Homogeneous human papilloma virus capsomere containing compositions, methods for manufacture, and the use thereof as diagnostic, prophylactic or therapy

Also Published As

Publication number Publication date
FR07C0026I2 (fr) 2012-08-03
DE60030698T2 (de) 2007-07-19
CY2007008I1 (el) 2009-11-04
CA2368391A1 (en) 2000-10-05
DE122007000032I1 (de) 2007-08-09
LU91328I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-03-01
LTPA2007002I1 (lt) 2020-03-25
CY2007010I1 (el) 2009-11-04
AU3909300A (en) 2000-10-16
LU91326I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-12-31
CA2368391C (en) 2011-06-07
JP4594534B2 (ja) 2010-12-08
NL300268I1 (nl) 2007-05-01
CY2007009I1 (el) 2010-07-28
EP1165126A1 (en) 2002-01-02
NL300270I1 (nl) 2007-05-01
ES2270822T3 (es) 2007-04-16
JP2002540167A (ja) 2002-11-26
PT1165126E (pt) 2006-12-29
CY2007010I2 (el) 2009-11-04
US20010021385A1 (en) 2001-09-13
DK1165126T3 (da) 2007-01-08
NL300269I1 (nl) 2007-05-01
DE122007000034I1 (de) 2007-08-09
FR07C0026I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2007-04-27
ATE339222T1 (de) 2006-10-15
DE60030698D1 (de) 2006-10-26
DE122007000033I1 (de) 2007-08-09
NL300269I2 (nl) 2008-07-01
AU778937B2 (en) 2004-12-23
LU91327I2 (fr) 2007-05-14
WO2000057906A1 (en) 2000-10-05
LU91327I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-03-01
CY2007009I2 (el) 2010-07-28
LU91328I2 (fr) 2007-05-14
CY1105779T1 (el) 2010-07-28
LTC1165126I2 (lt) 2020-04-27
SI1165126T1 (sl) 2006-12-31
LU91326I2 (fr) 2007-05-14
KR20020013516A (ko) 2002-02-20
EP1165126B1 (en) 2006-09-13
CY2007008I2 (el) 2009-11-04
US6245568B1 (en) 2001-06-12

Similar Documents

Publication Publication Date Title
AR023166A1 (es) Vacuna del virus de papiloma humano con particulas del tipo virus desensambladas y reensambladas
EA200300536A1 (ru) Неограниченные соматические стволовые клетки (ussc), полученные из пуповинной крови человека
AR077396A2 (es) EXPRESIoN OPTIMIZADA DE LA PROTEíNA DE LA CÁPSIDE L1 DEL VIRUS DE PAPILOMA HUMANO VPH45 EN LEVADURAS
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
AP1872A (en) Virus-like particles of human papillomavirus.
IN2009KN04355A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO2002022080A3 (en) Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
EA200400026A1 (ru) Ингибиторы вич-протеазы, содержащие их композиции, их фармацевтические применения и вещества для их синтеза
EP4400510A3 (en) Improved vaccines and methods for using the same
BRPI0514176A (pt) inibidores de replicação de hcv
AU2003261231A1 (en) Modified small interfering rna molecules and methods of use
WO2008034388A8 (fr) Particules virales de protéines de la capside provenant du papillomavirus humain de type 16/58/18/6/11 et leur procédé de préparation et leurs utilisations
EA200500834A1 (ru) Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1
WO2001087350A3 (en) Treatment of human papillomavirus (hpv)-infected cells
RS50977B (sr) Replikaciono defektni rnk-virusi kao vakcine
ES2145000T3 (es) Virus recombinante del avipox.
PE20081215A1 (es) Identificacion y caracterizacion de variantes de replicon de vhc con menor susceptibilidad a vhc-796, y metodos relacionados
MX2022009964A (es) Vacuna contra hpv.
WO2005052116A3 (en) Preservative-containing virus formulations
MX2023006038A (es) Vacunas contra el virus del papiloma humano y usos de estas para enfermedades asociadas a hpv.
AR039186A1 (es) Celulas madre indiferenciadas programables de origen monocitaro, su obtencion y uso
PT777669E (pt) Utilizacao de succinato de 4-(2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-ciclopenteno-1-metanol como agente antiviral
WO2003072725A3 (en) Recombinant negative strand virus rna expression systems and vaccines
MY162658A (en) Genes encoding major capsid protein l1 of human papilloma virus and use of the same
ATE453708T1 (de) Impfstoff gegen west nile virus